Tessa Buckle1,2, Danny M van Willigen1, Silvia J Spa1, Albertus W Hensbergen1, Steffen van der Wal1, Clarize M de Korne1, Mick M Welling1, Henk G van der Poel3, James C H Hardwick4, Fijs W B van Leeuwen5,3. 1. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 2. Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; and. 4. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands. 5. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands f.w.b.van_leeuwen@lumc.nl.
Abstract
The potential of receptor-mediated fluorescence-based image-guided surgery tracers is generally linked to the near-infrared emission profile and good-manufacturing-production availability of fluorescent dyes. Surprisingly, little is known about the critical interaction between the structural composition of the dyes and the pharmacokinetics of the tracers. In this study, a dual-modality tracer design was used to systematically and quantitatively evaluate the influence of elongation of the polymethine chain in a fluorescent cyanine dye on the imaging potential of a targeted tracer. Methods: As a model system, the integrin marker αvβ3 was targeted using arginylglycylaspartisc acid [RGD]-based vectors functionalized with a 111In-diethylenetriaminepentaacetic acid (DTPA) chelate and a fluorescent dye: (Cy3-(SO3)methyl-COOH [emission wavelength (λem), 580 nm], Cy5-(SO3)methyl-COOH [λem, 680 nm], or Cy7-(SO3)methyl-COOH [λem, 780 nm]). Tracers were analyzed for differences in photophysical properties, serum protein binding, chemical or optical stability, and signal penetration through tissue. Receptor affinities were evaluated using saturation and competition experiments. In vivo biodistribution (SPECT imaging and percentage injected dose per gram of tissue) was assessed in tumor-bearing mice and complemented with in vivo and ex vivo fluorescence images obtained using a clinical-grade multispectral fluorescence laparoscope. Results: Two carbon-atom-step variations in the polymethine chain of the fluorescent cyanine dyes were shown to significantly influence the chemical and photophysical characteristics (e.g., stability, brightness, and tissue penetration) of the hybrid RGD tracers. DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] structurally outperformed its Cy3 and Cy7 derivatives. Radioactivity-based evaluation of in vivo tracer pharmacokinetics yielded the lowest nonspecific uptake and highest tumor-to-background ratio for DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] (13.2 ± 1.7), with the Cy3 and Cy7 analogs trailing at respective tumor-to-background ratios of 5.7 ± 0.7 and 4.7 ± 0.7. Fluorescence-based assessment of tumor visibility revealed a similar trend. Conclusion: These findings underline that variations in the polymethine chain lengths of cyanine dyes have a profound influence on the photophysical properties, stability, and in vivo targeting capabilities of fluorescent imaging tracers. In a direct comparison, the intermediate-length dye (Cy5) yielded a superior c[RGDyK] tracer, compared with the shorter (Cy3) and longer (Cy7) analogs.
The potential of receptor-mediated fluorescence-based image-guided surgery tracers is generally linked to the near-infrared emission profile and good-manufacturing-production availability of fluorescent dyes. Surprisingly, little is known about the critical interaction between the structural composition of the dyes and the pharmacokinetics of the tracers. In this study, a dual-modality tracer design was used to systematically and quantitatively evaluate the influence of elongation of the polymethine chain in a fluorescent cyanine dye on the imaging potential of a targeted tracer. Methods: As a model system, the integrin marker αvβ3 was targeted using arginylglycylaspartisc acid [RGD]-based vectors functionalized with a 111In-diethylenetriaminepentaacetic acid (DTPA) chelate and a fluorescent dye: (Cy3-(SO3)methyl-COOH [emission wavelength (λem), 580 nm], Cy5-(SO3)methyl-COOH [λem, 680 nm], or Cy7-(SO3)methyl-COOH [λem, 780 nm]). Tracers were analyzed for differences in photophysical properties, serum protein binding, chemical or optical stability, and signal penetration through tissue. Receptor affinities were evaluated using saturation and competition experiments. In vivo biodistribution (SPECT imaging and percentage injected dose per gram of tissue) was assessed in tumor-bearing mice and complemented with in vivo and ex vivo fluorescence images obtained using a clinical-grade multispectral fluorescence laparoscope. Results: Two carbon-atom-step variations in the polymethine chain of the fluorescent cyanine dyes were shown to significantly influence the chemical and photophysical characteristics (e.g., stability, brightness, and tissue penetration) of the hybrid RGD tracers. DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] structurally outperformed its Cy3 and Cy7 derivatives. Radioactivity-based evaluation of in vivo tracer pharmacokinetics yielded the lowest nonspecific uptake and highest tumor-to-background ratio for DTPA-Cy5-(SO3)methyl-COOH-c[RGDyK] (13.2 ± 1.7), with the Cy3 and Cy7 analogs trailing at respective tumor-to-background ratios of 5.7 ± 0.7 and 4.7 ± 0.7. Fluorescence-based assessment of tumor visibility revealed a similar trend. Conclusion: These findings underline that variations in the polymethine chain lengths of cyanine dyes have a profound influence on the photophysical properties, stability, and in vivo targeting capabilities of fluorescent imaging tracers. In a direct comparison, the intermediate-length dye (Cy5) yielded a superior c[RGDyK] tracer, compared with the shorter (Cy3) and longer (Cy7) analogs.
Authors: Albertus W Hensbergen; Tessa Buckle; Danny M van Willigen; Margret Schottelius; Mick M Welling; Felicia A van der Wijk; Tobias Maurer; Henk G van der Poel; Gabri van der Pluijm; Wytske M van Weerden; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: J Nucl Med Date: 2019-09-03 Impact factor: 10.057
Authors: Tessa Buckle; Albertus W Hensbergen; Danny M van Willigen; Frank Bosse; Kevin Bauwens; Rob C M Pelger; Fijs W B van Leeuwen Journal: EJNMMI Res Date: 2021-05-29 Impact factor: 3.138
Authors: Margret Schottelius; Alexander Wurzer; Katharina Wissmiller; Roswitha Beck; Maximilian Koch; Dimitrios Gorpas; Johannes Notni; Tessa Buckle; Matthias N van Oosterom; Katja Steiger; Vasilis Ntziachristos; Markus Schwaiger; Fijs W B van Leeuwen; Hans-Jürgen Wester Journal: J Nucl Med Date: 2018-09-20 Impact factor: 10.057
Authors: Pieterjan Debie; Noemi B Declerck; Danny van Willigen; Celine M Huygen; Bieke De Sloovere; Lukasz Mateusiak; Jessica Bridoux; Janik Puttemans; Nick Devoogdt; Fijs W B van Leeuwen; Sophie Hernot Journal: Biomolecules Date: 2021-02-26
Authors: Syed Muhammad Usama; Sierra C Marker; Servando Hernandez Vargas; Solmaz AghaAmiri; Sukhen C Ghosh; Naruhiko Ikoma; Hop S Tran Cao; Martin J Schnermann; Ali Azhdarinia Journal: Cancers (Basel) Date: 2022-03-23 Impact factor: 6.639
Authors: Joachim Pfister; Dominik Summer; Milos Petrik; Marta Khoylou; Alexander Lichius; Piriya Kaeopookum; Laurin Kochinke; Thomas Orasch; Hubertus Haas; Clemens Decristoforo Journal: Biomolecules Date: 2020-01-22